News >

NICE Rejects Polatuzumab Vedotin Combo in Relapsed/Refractory DLBCL

Kristi Rosa
Published: Wednesday, Feb 26, 2020

blood cellsThe United Kingdom’s National Institute for Health and Care Excellence (NICE) has chosen not to recommend the combination of polatuzumab vedotin (Polivy) with rituximab (Rituxan) and bendamustine (BR) for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who cannot undergo hematopoietic stem cell transplant.1

Although clinical evidence suggests that patients who receive the combination experience prolonged progression-free and overall survival compared with those who receive BR alone, final data from the phase Ib/II GOG29365 trial (NCT02257567) examining the use of the triplet are not yet available, the agency stated in the appraisal consultation document.

Moreover, the cost-effectiveness estimates for the polatuzumab vedotin combination remain uncertain due to limitations in the data available and methods used, NICE added.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication